HUTCHMED (NASDAQ:HCM) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

Shares of HUTCHMED (China) Limited (NASDAQ:HCM) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $14.51 and traded as high as $16.85. HUTCHMED shares last traded at $16.75, with a volume of 66,974 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Price Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The business has a 50 day moving average of $14.51 and a 200 day moving average of $16.67.

Institutional Investors Weigh In On HUTCHMED

A number of hedge funds have recently bought and sold shares of HCM. Jane Street Group LLC grew its position in HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after acquiring an additional 49,366 shares in the last quarter. State Street Corp raised its holdings in HUTCHMED by 0.9% during the 3rd quarter. State Street Corp now owns 349,524 shares of the company’s stock valued at $6,826,000 after buying an additional 3,078 shares during the period. ABC Arbitrage SA bought a new stake in HUTCHMED in the fourth quarter worth $500,000. XY Capital Ltd bought a new position in HUTCHMED during the fourth quarter valued at $673,000. Finally, Crossmark Global Holdings Inc. boosted its stake in shares of HUTCHMED by 10.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock worth $268,000 after purchasing an additional 1,799 shares during the period. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.